Market cap
$3,561 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
--
P/B Ratio
4.4
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -78.10 | -60.12 |
| EBIT | 0.70 | -2.77 | -6.76 | -225.64 | -257.93 |
| Net Profit | 0.70 | -2.77 | -6.77 | -225.66 | -255.68 |
| EPS | 1.06 | 5.94 | -1.07 | -185.38 | -257.35 |
| Book Value | -- | -- | -20.08 | -9.69 | -8.42 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -43.93 | -317.41 | -14,188.37 | -- | -- |
| Net Margin
| -- | -545.63 | -14,191.20 | -- | -- |
| Return on equity
| -32.37 | -31.43 | -55.32 | -45.69 | -37.40 |
| Return on Capital
| -31.04 | -29.92 | -- | -44.02 | -35.80 |
| Return on Assets
| -28.42 | -25.47 | -40.83 | -40.69 | -33.45 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.04 | 0.04 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
--
|
-44.02
|
-35.80
|
-13.29
|
-30.62
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-55.32
Lower than Peers by 14.99
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
-55.32
|
-45.69
|
-37.40
|
-14.01
|
-32.52
|
|
Peer Median
|
-40.33
|
--
|
--
|
--
|
--
|
ROA
-40.83
Lower than Peers by 9.58
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
-40.83
|
-40.69
|
-33.45
|
-11.11
|
-22.76
|
|
Peer Median
|
-31.24
|
--
|
--
|
--
|
--
|
EBIT Margin
-14,188.37
Lower than Peers by 14,105.78
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
-14,188.37
|
--
|
--
|
-43.93
|
-300.54
|
|
Peer Median
|
-82.60
|
--
|
--
|
--
|
--
|
Net Margin
-14,191.20
Lower than Peers by 14,099.91
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
-14,191.20
|
--
|
--
|
-43.94
|
-300.56
|
|
Peer Median
|
-91.30
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
--
|
--
|
-1.00
|
2.05
|
1.23
|
|
Peer Median
|
54.03
|
--
|
--
|
--
|
--
|
EBIT Growth
-6.76
Lower than Peers by 5.74
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
-6.76
|
-2.10
|
-245.66
|
55.46
|
-10.22
|
|
Peer Median
|
-1.02
|
--
|
--
|
--
|
--
|
Net Profit Growth
-6.77
Higher than Peers by 0.77
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
-6.77
|
-21.23
|
-191.12
|
55.45
|
-12.19
|
|
Peer Median
|
-7.53
|
--
|
--
|
--
|
--
|
EPS Growth
-1.07
Lower than Peers by 15.30
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
-1.07
|
-0.18
|
-1.37
|
0.57
|
-0.03
|
|
Peer Median
|
14.23
|
--
|
--
|
--
|
--
|
Book Value Growth
-25.57
Lower than Peers by 15.44
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
-25.57
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.13
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
--
|
0.04
|
0.04
|
0.05
|
0.06
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
--
|
0.01
|
0.01
|
0.01
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
8.37
Higher than Peers by 2.56
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
8.37
|
9.16
|
8.46
|
13.65
|
3.77
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
8.32
Higher than Peers by 2.63
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
8.32
|
--
|
--
|
13.65
|
3.78
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
--
|
--
|
--
|
--
|
-22.06
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
108.96
Higher than Peers by 89.95
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
108.96
|
--
|
--
|
1.03
|
8.56
|
|
Peer Median
|
19.01
|
--
|
--
|
--
|
--
|
Asset Turnover
0.00
Lower than Peers by 0.06
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
0.00
|
--
|
--
|
0.25
|
0.08
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
--
|
--
|
--
|
7.02
|
17.69
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
--
|
--
|
0.00
|
-54.59
|
-259.71
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
--
|
236.25
|
483.10
|
134.00
|
196.57
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
--
|
--
|
--
|
-181.58
|
-438.58
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
--
|
-5.65
|
-8.20
|
-20.43
|
-11.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
4.36
Lower than Peers by 0.97
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
4.36
|
2.86
|
2.82
|
2.88
|
3.54
|
|
Peer Median
|
5.33
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
86.48
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
86.48
|
-4.15
|
-5.44
|
-15.45
|
-7.67
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
3,561
Higher than Peers by 3,420
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
3,561
|
--
|
--
|
--
|
--
|
|
Peer Median
|
142
|
--
|
--
|
--
|
--
|